Key Points
- Director Kevin Mclaughlin purchased 50,000 shares of Invivyd at an average price of $2.50 per share on Nov. 19, a $125,000 purchase disclosed in an SEC filing.
- Invivyd shares traded at $2.50 (52‑week range $0.35–$3.07) while the company reports negative earnings and margins (last quarter EPS -$0.06, net margin -119.63%), with analysts forecasting a -1.64 EPS for the year.
- Institutional investors own about 70.36% of the stock and analyst coverage is mixed (three Buys, one Hold, one Sell) yielding a consensus rating of "Hold" and a consensus price target of $7.33.
Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Kevin Mclaughlin bought 50,000 shares of the business's stock in a transaction that occurred on Wednesday, November 19th. The stock was purchased at an average price of $2.50 per share, with a total value of $125,000.00. Following the completion of the purchase, the director directly owned 50,000 shares in the company, valued at $125,000. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Invivyd Stock Performance
Shares of NASDAQ IVVD traded up $0.10 during trading hours on Friday, reaching $2.50. 1,510,095 shares of the stock were exchanged, compared to its average volume of 7,942,099. Invivyd, Inc. has a 52 week low of $0.35 and a 52 week high of $3.07. The firm has a market capitalization of $581.63 million, a price-to-earnings ratio of -5.31 and a beta of 0.64. The stock's fifty day simple moving average is $1.67 and its 200 day simple moving average is $1.10.
Invivyd (NASDAQ:IVVD - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01). The company had revenue of $13.13 million for the quarter, compared to the consensus estimate of $12.00 million. Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%. Research analysts predict that Invivyd, Inc. will post -1.64 EPS for the current fiscal year.
Institutional Trading of Invivyd
Several hedge funds and other institutional investors have recently bought and sold shares of IVVD. Catalyst Funds Management Pty Ltd bought a new stake in shares of Invivyd in the second quarter worth about $27,000. Vanguard Personalized Indexing Management LLC boosted its stake in Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock valued at $29,000 after purchasing an additional 28,146 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Invivyd by 330.5% during the 3rd quarter. Bank of America Corp DE now owns 49,252 shares of the company's stock valued at $54,000 after acquiring an additional 37,811 shares during the last quarter. Nuveen LLC purchased a new stake in Invivyd during the first quarter valued at $65,000. Finally, XTX Topco Ltd bought a new stake in shares of Invivyd during the 1st quarter valued at $66,000. Institutional investors own 70.36% of the company's stock.
Analysts Set New Price Targets
IVVD has been the subject of several research analyst reports. HC Wainwright boosted their target price on Invivyd from $5.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday, October 31st. Zacks Research upgraded Invivyd from a "strong sell" rating to a "hold" rating in a report on Thursday, November 13th. D. Boral Capital increased their price target on Invivyd from $1.00 to $2.00 and gave the stock a "buy" rating in a report on Monday, October 6th. Weiss Ratings reissued a "sell (e+)" rating on shares of Invivyd in a research report on Friday, October 31st. Finally, Cantor Fitzgerald began coverage on shares of Invivyd in a report on Monday, October 6th. They set an "overweight" rating and a $10.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Invivyd has a consensus rating of "Hold" and a consensus price target of $7.33.
Check Out Our Latest Report on IVVD
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
